Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7568282 in early Parkinson's disease
NL-OMON61762Phase 2Not yet recruiting
- Sponsor
- Roche
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in Parkinson's disease (PD) comparing RO7568282 with Placebo (2 arms). Primary endpoint: Time to confirmed motor progression event. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
RO7568282
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON61762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61762.